Maung Myo Htut, M.D.

"There’s a real need for additional therapies for myeloma." — Maung Myo Htut, M.D.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
California State Medical License (active)
Colorado State Medical License (active)
1997, General Medical Council, UK
ECFMG certified
Diplomate, American Board of Internal Medicine
1998, Education Commission for Foreign Medical Graduates
1995, M.B., B.S., Institute of Medicine (1), Yangon, Myanmar
2009 - 2010, HCT Fellow, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, CA
2007 -2009, Oncology Fellow, University of Colorado, Denver, CO
1999 -2002, Resident, Internal Medicine, Harbor Hospital, Baltimore, MD
1995 -1996, Intern, Internal Medicine, Yangon General Hospital, Yangon, Myanmar
2019 - present, Associate Professor, Division of Multiple Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2010 - 2019, Assistant Clinical Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2009 - 2010, Hematopoietic Cell Transplantation Fellow, City of Hope, Duarte, CA
2007 - 2009, Oncology Fellow, University of Colorado, Denver, CO
2002 - 2007, Hospitalist , High desert Medical Group, Lancaster, CA
1999 - 2002, Residency Program (Internal Medicine) Harbor Hospital, Baltimore, MD
Publications
-
Amanam, I, Yao, J, Puing, A, et al. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Cancer Med. 2023; 12: 11248-11253. doi:10.1002/cam4.5832
-
Taxiarchis Kourelis, Radhika Bansal, Jesus Berdeja, David Siegel, Krina Patel, Sham Mailankody, Myo Htut, Nina Shah, Sandy W. Wong, Surbhi Sidana, Andrew J. Cowan, Melissa Alsina, Adam Cohen, Sarah A. Holstein, Leif Bergsagel, Sikander Ailawadhi, Noopur Raje, Binod Dhakal, Adriana Rossi, Yi Lin, Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience,Transplantation and Cellular Therapy, Volume 29, Issue 4,2023,Pages 255-258,ISSN 2666-6367
-
Myo Htut, Binod Dhakal, Adam D. Cohen, Thomas Martin, Jesus G Berdeja, Saad Z. Usmani, Mounzer Agha, Carolyn C. Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, Tzu-min Yeh, Xiaoying Xu, Lida Pacaud, Muhammad Akram, Sundar Jagannath, Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study, Clinical Lymphoma Myeloma and Leukemia,2023,,ISSN 2152-2650.
- NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049. PMID: 31590151
- Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, Wong CW, Chang WC, Thomas SH, Sanchez JF, Yang L, Brown CE, Pichiorri F, Htut M, Krishnan AY, Forman SJ. Clin Cancer Res. 2018 Jan 1;24(1):106-119. doi: 10.1158/1078-0432.CCR-17-0344. Epub 2017 Oct 23. PMID: 29061640
- Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now? Htut M. Curr Hematol Malig Rep. 2019 Feb;14(1):1-10. doi: 10.1007/s11899-019-0492-z. PMID: 30666505
- NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049. PMID: 31590151
- Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, Wong CW, Chang WC, Thomas SH, Sanchez JF, Yang L, Brown CE, Pichiorri F, Htut M, Krishnan AY, Forman SJ. Clin Cancer Res. 2018 Jan 1;24(1):106-119. doi: 10.1158/1078-0432.CCR-17-0344. Epub 2017 Oct 23. PMID: 29061640
- Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Survival. Biol Blood Marrow Transplant. 2017 Oct 24. pii: S1083-8791(17)30793-0. DOI: 10.1016/j.bbmt.2017.10.024. [Epub ahead of print].
- Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL.A phase !dose-escalation study on filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 2016 Nov 15;122(21):3327-333.5. DOI: 10.1002/cncr.30174. PMID: 27433944.
- Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ, Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-hodgkin lymphoma. Haematologica. 2015 Mar; 100(3):357-62. DOI: 10.3324/haematol.2014.117473 PMID:25596263.
- Twice-weekly Oral Ixazomib Citrate (MLN9708), an Investigational Proteasome Inhibitor, in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data -ASH poster 2013.
- Deauna-Limayo D, Rajabi B, Qiu W, Htut M, Swetenham J. Kaposi's Sacroma After Non-Myeloablative Hematopoietic Stem Cell Transplant: Response to Withdraw! of Immunosuppressant Therapy Correlated with Whole Blood Human Herpes Virus-8 RT-PCR levels. Leuk Lymphoma. 2013 Jan 24. [Epub ahead of print].
- Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J, Krishnan AY, Karanes C, Htut M, Somlo G, Forman SJ. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol. 2013 Jan;l60(2):199-206. DOI: 10.1111/bjh.12123. Epub 2112 Nov 15.
- Krishnan AY, Mei M, Sun CL, Thomas SH, Teh JB, Kang T, Htut M, Somlo G, Sahebi F, Forman SJ, Bhatia S. Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant, 2012 Oct 13. Pii: Sl083-8791(12)00418-l doi: 10.1016/j.bbmt.2012.09.023 Epub 2012 Oct 13.
Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy.